With Vidaza standing firm against competitors, Pharmion Corp. is adding the Phase II anthracycline amrubicin for lung cancer to its pipeline in the $55 million net-of-cash buyout of privately held Cabrellis Pharmaceuticals Inc. (BioWorld Today) Read More
